Thor G Theander

List of Publications by Year
in descending order

251 papers	16,202 citations	17440 63 h-index	22832 112 g-index
253 all docs	253 docs citations	253 times ranked	9730 citing authors

#	Article	IF	Citations
1	Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1Î² for Treatment of Allergic Contact Dermatitis. Vaccines, 2022, 10, 828.	4.4	0
2	Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature. Pharmaceutics, 2022, 14, 1301.	4.5	4
3	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	12.8	79
4	The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration. Vaccines, 2021, 9, 131.	4.4	4
5	Reduced Birth Weight Caused by Sextuple Drug-Resistant Plasmodium falciparum Infection in Early Second Trimester. Journal of Infectious Diseases, 2021, 224, 1605-1613.	4.0	4
6	Development of a bispecific immune engager using a recombinant malaria protein. Cell Death and Disease, 2021, 12, 353.	6.3	5
7	Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems. Vaccines, 2021, 9, 539.	4.4	6
8	Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding. Nature Communications, 2021, 12, 2956.	12.8	30
9	The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility. Journal of Biological Chemistry, 2021, 297, 101391.	3.4	10
10	Detection of VAR2CSA-Captured Colorectal Cancer Cells from Blood Samples by Real-Time Reverse Transcription PCR. Cancers, 2021, 13, 5881.	3.7	1
11	A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice. Vaccines, 2020, 8, 389.	4.4	13
12	Immunization with virus-like particles conjugated to CIDRÎ±1 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies. Malaria Journal, 2020, 19, 132.	2.3	5
13	Optimization of rVAR2-Based Isolation of Cancer Cells in Blood for Building a Robust Assay for Clinical Detection of Circulating Tumor Cells. International Journal of Molecular Sciences, 2020, 21, 2401.	4.1	6
14	First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. Clinical Infectious Diseases, 2019, 69, 1509-1516.	5.8	111
15	Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein. Cells, 2019, 8, 998.	4.1	49
16	Acquisition of Antibodies Against Endothelial Protein C Receptorâ€“Binding Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 in Children with Severe Malaria. Journal of Infectious Diseases, 2019, 219, 808-818.	4.0	22
17	A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine. Scientific Reports, 2019, 9, 5260.	3.3	45
18	Anemia in late pregnancy induces an adaptive response in fetoplacental vascularization. Placenta, 2019, 80, 49-58.	1.5	10

#	Article	IF	Citations
19	Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies. EBioMedicine, 2019, 39, 358-368.	6.1	20
20	Malaria in Early Pregnancy and the Development of the Placental Vasculature. Journal of Infectious Diseases, 2019, 220, 1425-1434.	4.0	40
21	Supporting capacity for research on malaria in Africa. BMJ Global Health, 2018, 3, e000723.	4.7	3
22	Virus-like particle display of HER2 induces potent anti-cancer responses. OncoImmunology, 2018, 7, e1408749.	4.6	82
23	Immunization with Recombinant Plasmodium falciparum Erythrocyte Membrane Protein 1 CIDRÎ±1 Domains Induces Domain Subtype Inhibitory Antibodies. Infection and Immunity, 2018, 86, .	2.2	12
24	The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nature Communications, 2018, 9, 3279.	12.8	109
25	The Severity of Plasmodium falciparum Infection Is Associated with Transcript Levels of var Genes Encoding Endothelial Protein C Receptor-Binding P. falciparum Erythrocyte Membrane Protein 1. Infection and Immunity, 2017, 85, .	2.2	62
26	Structure-Guided Identification of a Family of Dual Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria. Cell Host and Microbe, 2017, 21, 403-414.	11.0	140
27	Pre-clinical and clinical development of the first placental malaria vaccine. Expert Review of Vaccines, 2017, 16, 613-624.	4.4	16
28	Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Vaccine, 2017, 35, 3726-3732.	3.8	60
29	Comparison of functional assays used in the clinical development of a placental malaria vaccine. Vaccine, 2017, 35, 610-618.	3.8	7
30	Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration. International Journal of Cancer, 2017, 140, 1597-1608.	5.1	14
31	Plasmodium falciparum Infection Early in Pregnancy has Profound Consequences for Fetal Growth. Journal of Infectious Diseases, 2017, 216, 1601-1610.	4.0	33
32	Parasites Causing Cerebral Falciparum Malaria Bind Multiple Endothelial Receptors and Express EPCR and ICAM-1-Binding PfEMP1. Journal of Infectious Diseases, 2017, 215, 1918-1925.	4.0	65
33	Cellulose filtration of blood from malaria patients for improving ex vivo growth of Plasmodium falciparum parasites. Malaria Journal, 2017, 16, 69.	2.3	4
34	Adhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue: a novel model of placental malaria. Malaria Journal, 2016, 15, 292.	2.3	25
35	Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1. PLoS Pathogens, 2016, 12, e1005831.	4.7	79
36	Bacterial superglue enables easy development of efficient virus-like particle based vaccines. Journal of Nanobiotechnology, 2016, 14, 30.	9.1	161

#	Article	IF	Citations
37	Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. Molecular Cancer Research, 2016, 14, 1288-1299.	3.4	57
38	Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malaria Journal, 2016, 15, 545.	2.3	48
39	Plasma Ang2 and ADAM17 levels are elevated during clinical malaria; Ang2 level correlates with severity and expression of EPCR-binding PfEMP1. Scientific Reports, 2016, 6, 35950.	3.3	14
40	Plasmodium falciparum var genes expressed in children with severe malaria encode <scp>CIDR</scp> Î±1 domains. EMBO Molecular Medicine, 2016, 8, 839-850.	6.9	81
41	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. Malaria Journal, 2016, 15, 258.	2.3	23
42	Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting. Sensing and Bio-Sensing Research, 2016, 9, 23-30.	4.2	16
43	Haplotypes of the endothelial protein C receptor (EPCR) gene are not associated with severe malaria in Tanzania. Malaria Journal, 2015, 14, 474.	2.3	8
44	Protein C system defects inflicted by the malaria parasite protein PfEMP1 can be overcome by a soluble EPCR variant. Thrombosis and Haemostasis, 2015, 114, 1038-1048.	3.4	46
45	IgG Antibodies to Endothelial Protein C Receptor-Binding Cysteine-Rich Interdomain Region Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 Are Acquired Early in Life in Individuals Exposed to Malaria. Infection and Immunity, 2015, 83, 3096-3103.	2.2	45
46	Structural Conservation Despite Huge Sequence Diversity Allows EPCR Binding by the PfEMP1 Family Implicated in Severe Childhood Malaria. Cell Host and Microbe, 2015, 17, 118-129.	11.0	141
47	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. New England Journal of Medicine, 2015, 373, 2025-2037.	27.0	332
48	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell, 2015, 28, 500-514.	16.8	169
49	The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. PLoS ONE, 2015, 10, e0135406.	2.5	42
50	A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS ONE, 2015, 10, e0143071.	2.5	53
51	Utilizing Nanobody Technology to Target Non-Immunodominant Domains of VAR2CSA. PLoS ONE, 2014, 9, e84981.	2.5	20
52	Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Medicine, 2014, 11, e1001685.	8.4	367
53	DNA secondary structures are associated with recombination in major Plasmodium falciparum variable surface antigen gene families. Nucleic Acids Research, 2014, 42, 2270-2281.	14.5	36
54	PfSETvs methylation of histone H3K36 represses virulence genes in Plasmodium falciparum. Nature, 2013, 499, 223-227.	27.8	219

#	Article	IF	Citations
55	Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature, 2013, 498, 502-505.	27.8	460
56	Human genetic polymorphisms in the Knops blood group are not associated with a protective advantage against Plasmodium falciparum malaria in Southern Ghana. Malaria Journal, 2013, 12, 400.	2.3	17
57	Plasmodium falciparumMutant Haplotype Infection during Pregnancy Associated with Reduced Birthweight, Tanzania. Emerging Infectious Diseases, 2013, 19, .	4.3	68
58	A Novel Domain Cassette Identifies Plasmodium falciparum PfEMP1 Proteins Binding ICAM-1 and Is a Target of Cross-Reactive, Adhesion-Inhibitory Antibodies. Journal of Immunology, 2013, 190, 240-249.	0.8	101
59	Multilaboratory Approach to Preclinical Evaluation of Vaccine Immunogens for Placental Malaria. Infection and Immunity, 2013, 81, 487-495.	2.2	36
60	Malaria and Fetal Growth Alterations in the 3rd Trimester of Pregnancy: A Longitudinal Ultrasound Study. PLoS ONE, 2013, 8, e53794.	2.5	37
61	Expression of the Domain Cassette 8 Plasmodium falciparum Erythrocyte Membrane Protein 1 Is Associated with Cerebral Malaria in Benin. PLoS ONE, 2013, 8, e68368.	2.5	59
62	Plasmodium falciparum Expressing Domain Cassette 5 Type PfEMP1 (DC5-PfEMP1) Bind PECAM1. PLoS ONE, 2013, 8, e69117.	2.5	36
63	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
64	Structural and Functional Insight into How the Plasmodium falciparum VAR2CSA Protein Mediates Binding to Chondroitin Sulfate A in Placental Malaria. Journal of Biological Chemistry, 2012, 287, 23332-23345.	3.4	154
65	Factors associated with and causes of perinatal mortality in northeastern Tanzania. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 1061-1068.	2.8	55
66	Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1791-800.	7.1	232
67	The effect of adjuvants on the immune response induced by a DBL4É›-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine, 2012, 30, 572-579.	3.8	14
68	Expression of a type B RIFIN in Plasmodium falciparum merozoites and gametes. Malaria Journal, 2012, 11, 429.	2.3	23
69	Reliability of rapid diagnostic tests in diagnosing pregnancy-associated malaria in north-eastern Tanzania. Malaria Journal, 2012, 11, 211.	2.3	26
70	Evidence for in vitro and in vivo expression of the conserved VAR3 (type 3) plasmodium falciparum erythrocyte membrane protein 1. Malaria Journal, 2012, 11, 129.	2.3	25
71	Identification and Characterization of B-Cell Epitopes in the DBL4Îµ Domain of VAR2CSA. PLoS ONE, 2012, 7, e43663.	2.5	10
72	IgG Responses to Anopheles gambiae Salivary Antigen gSG6 Detect Variation in Exposure to Malaria Vectors and Disease Risk. PLoS ONE, 2012, 7, e40170.	2.5	44

#	Article	IF	Citations
73	Development of a Fetal Weight Chart Using Serial Trans-Abdominal Ultrasound in an East African Population: A Longitudinal Observational Study. PLoS ONE, 2012, 7, e44773.	2.5	39
74	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
75	High efficacy of anti DBL4É›-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine, 2011, 29, 437-443.	3.8	46
76	Differential Induction of Functional IgG Using the Plasmodium falciparum Placental Malaria Vaccine Candidate VAR2CSA. PLoS ONE, 2011, 6, e17942.	2.5	16
77	Antibodies against PfEMP1, RIFIN, MSP3 and GLURP Are Acquired during Controlled Plasmodium falciparum Malaria Infections in NaÃ¯ve Volunteers. PLoS ONE, 2011, 6, e29025.	2.5	44
78	Pattern of Preâ€existing IgG Subclass Responses to a Panel of Asexual Stage Malaria Antigens Reported During the Lengthy Dry Season in Daraweesh, Sudan. Scandinavian Journal of Immunology, 2011, 74, 390-396.	2.7	1
79	Spatial variation and socio-economic determinants of Plasmodium falciparum infection in northeastern Tanzania. Malaria Journal, 2011, 10, 145.	2.3	22
80	Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania. Malaria Journal, 2011, 10, 176.	2.3	60
81	Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 168-172.	2.8	17
82	Prevalence of Single Nucleotide Polymorphisms in the Plasmodium falciparum Multidrug Resistance Gene (Pfmdr-1) in Korogwe District in Tanzania Before and After Introduction of Artemisinin-Based Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2011, 85, 979-983.	1.4	36
83	Positive Selection of Plasmodium falciparum Parasites With Multiple var2csa-Type PfEMP1 Genes During the Course of Infection in Pregnant Women. Journal of Infectious Diseases, 2011, 203, 1679-1685.	4.0	21
84	The Chondroitin Sulfate A-binding Site of the VAR2CSA Protein Involves Multiple N-terminal Domains. Journal of Biological Chemistry, 2011, 286, 15908-15917.	3.4	77
85	Serological Evidence of Discrete Spatial Clusters of Plasmodium falciparum Parasites. PLoS ONE, 2011, 6, e21711.	2.5	34
86	The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs. Malaria Journal, 2010, 9, 100.	2.3	21
87	Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies. Malaria Journal, 2010, 9, 11.	2.3	37
88	Clustering of malaria treatment failure (TF) in Daraweesh: Hints for host genetic susceptibility to TF with emphasis on immune-modulating SNPs. Infection, Genetics and Evolution, 2010, 10, 481-486.	2.3	3
89	Association of a Single Nucleotide Polymorphism in the C-Reactive Protein Gene (-286) with Susceptibility to Plasmodium falciparum Malaria. Molecular Medicine, 2010, 16, 27-33.	4.4	12
90	Hierarchical, Domain Type-Specific Acquisition of Antibodies to Plasmodium falciparum Erythrocyte Membrane Protein 1 in Tanzanian Children. Infection and Immunity, 2010, 78, 4653-4659.	2.2	61

#	Article	IF	Citations
91	Surface Co-Expression of Two Different PfEMP1 Antigens on Single Plasmodium falciparum-Infected Erythrocytes Facilitates Binding to ICAM1 and PECAM1. PLoS Pathogens, 2010, 6, e1001083.	4.7	88
92	Plasmodium falciparum Erythrocyte Membrane Protein 1 Diversity in Seven Genomes â€“ Divide and Conquer. PLoS Computational Biology, 2010, 6, e1000933.	3.2	302
93	Full-Length Recombinant Plasmodium falciparum VAR2CSA Binds Specifically to CSPG and Induces Potent Parasite Adhesion-Blocking Antibodies. Journal of Molecular Biology, 2010, 397, 826-834.	4.2	106
94	Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh. Vaccine, 2010, 28, 1732-1739.	3.8	18
95	Structure function analysis of P. falciparum VAR2CSA. Malaria Journal, 2010, 9, .	2.3	1
96	Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytes. Malaria Journal, 2010, 9, 325.	2.3	10
97	A progressive declining in the burden of malaria in north-eastern Tanzania. Malaria Journal, 2010, 9, 216.	2.3	113
98	Identification of a major rif transcript common to gametocytes and sporozoites of Plasmodium falciparum. Malaria Journal, 2010, 9, 147.	2.3	28
99	Induction of Adhesion-Inhibitory Antibodies against PlacentalPlasmodium falciparumParasites by Using Single Domains of VAR2CSA. Infection and Immunity, 2009, 77, 2482-2487.	2.2	92
100	Sequential, Ordered Acquisition of Antibodies to Plasmodium falciparum Erythrocyte Membrane Protein 1 Domains. Journal of Immunology, 2009, 183, 3356-3363.	0.8	111
101	Parasite threshold associated with clinical malaria in areas of different transmission intensities in north eastern Tanzania. BMC Medical Research Methodology, 2009, 9, 75.	3.1	13
102	Preferential transcription of conserved rif genes in two phenotypically distinct Plasmodium falciparum parasite lines. International Journal for Parasitology, 2009, 39, 655-664.	3.1	28
103	The Plasmodium falciparum var gene transcription strategy at the onset of blood stage infection in a human volunteer. Parasitology International, 2009, 58, 478-480.	1.3	57
104	Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria. Malaria Journal, 2009, 8, 306.	2.3	18
105	Chondroitin sulphate A (CSA)-binding of single recombinant Duffy-binding-like domains is not restricted to Plasmodium falciparum Erythrocyte Membrane Protein 1 expressed by CSA-binding parasites. International Journal for Parasitology, 2009, 39, 1195-1204.	3.1	45
106	Five-Year Surveillance of Molecular Markers of Plasmodium falciparum Antimalarial Drug Resistance in Korogwe District, Tanzania: Accumulation of the 581G Mutation in the P. falciparum Dihydropteroate Synthase Gene. American Journal of Tropical Medicine and Hygiene, 2009, 80, 523-527.	1.4	60
107	CD36 selection of 3D7 Plasmodium falciparum associated with severe childhood malaria results in reduced VAR4 expression. Malaria Journal, 2008, 7, 204.	2.3	5
108	A semi-automated multiplex high-throughput assay for measuring IgG antibodies against Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) domains in small volumes of plasma. Malaria Journal, 2008, 7, 108.	2.3	52

#	Article	IF	Citations
109	Identification of glycosaminoglycan binding regions in the Plasmodium falciparum encoded placental sequestration ligand, VAR2CSA. Malaria Journal, 2008, 7, 104.	2.3	27
110	A method for visualizing surface-exposed and internal PfEMP1 adhesion antigens in Plasmodium falciparum infected erythrocytes. Malaria Journal, 2008, 7, 101.	2.3	13
111	Structural Insight into Epitopes in the Pregnancy-Associated Malaria Protein VAR2CSA. PLoS Pathogens, 2008, 4, e42.	4.7	74
112	Differences in Human Antibody Reactivity to Plasmodium falciparum Variant Surface Antigens Are Dependent on Age and Malaria Transmission Intensity in Northeastern Tanzania. Infection and Immunity, 2008, 76, 2706-2714.	2.2	28
113	VAR2CSA Expression on the Surface of Placentaâ€DerivedPlasmodium falciparumâ€“Infected Erythrocytes. Journal of Infectious Diseases, 2008, 198, 1071-1074.	4.0	54
114	Plasmodium falciparum Transcriptome Analysis Reveals Pregnancy Malaria Associated Gene Expression. PLoS ONE, 2008, 3, e1855.	2.5	44
115	Immunoglobulin G Antibody Reactivity to a Group A Plasmodium falciparum Erythrocyte Membrane Protein 1 and Protection from P. falciparum Malaria. Infection and Immunity, 2007, 75, 2415-2420.	2.2	33
116	3D7-Derived Plasmodium falciparum Erythrocyte Membrane Protein 1 Is a Frequent Target of Naturally Acquired Antibodies Recognizing Protein Domains in a Particular Pattern Independent of Malaria Transmission Intensity. Journal of Immunology, 2007, 178, 428-435.	0.8	20
117	Developing Plasmodium falciparum malaria vaccines for populations living in areas with stable parasite transmission. International Journal of Biotechnology, 2007, 9, 292.	1.2	0
118	Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malaria Journal, 2007, 6, 153.	2.3	27
119	Changes in var gene mRNA levels during erythrocytic development in two phenotypically distinct Plasmodium falciparum parasites. Malaria Journal, 2007, 6, 78.	2.3	38
120	Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Molecular Microbiology, 2007, 63, 335-347.	2.5	97
121	Plasmodium falciparum: VAR2CSA expressed during pregnancy-associated malaria is partially resistant to proteolytic cleavage by trypsin. Experimental Parasitology, 2007, 117, 1-8.	1.2	30
122	The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: Does ultraviolet light (UVB) radiation play a role?. Medical Hypotheses, 2006, 66, 993-999.	1.5	28
123	Pathology of post-kala-azar dermal leishmaniasis: a light microscopical, immunohistochemical, and ultrastructural study of skin lesions and draining lymph nodes. Journal of Cutaneous Pathology, 2006, 33, 778-787.	1.3	26
124	Determinants of Variant Surface Antigen Antibody Response in Severe Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission. Scandinavian Journal of Immunology, 2006, 63, 232-240.	2.7	5
125	Leishmania donovani: An in vitro study of antimony-resistant amphotericin B-sensitive isolates. Experimental Parasitology, 2006, 114, 247-252.	1.2	18
126	Baculovirus-Expressed Constructs Induce Immunoglobulin G That Recognizes VAR2CSA on Plasmodium falciparum- Infected Erythrocytes. Infection and Immunity, 2006, 74, 4357-4360.	2.2	58

#	Article	IF	Citations
127	Limited Cross-Reactivity among Domains of the Plasmodium falciparum Clone 3D7 Erythrocyte Membrane Protein 1 Family. Infection and Immunity, 2006, 74, 6778-6784.	2.2	25
128	Programmed Transcription of the var Gene Family, but Not of stevor , in Plasmodium falciparum Gametocytes. Eukaryotic Cell, 2006, 5, 1206-1214.	3.4	63
129	Occurrence of the Southeast Asian/South American SVMNT Haplotype of the Chloroquineâ€Resistance Transporter Gene inPlasmodium falciparumin Tanzania. Journal of Infectious Diseases, 2006, 193, 1738-1741.	4.0	78
130	Levels of Plasma Immunoglobulin G with Specificity against the Cysteine-Rich Interdomain Regions of a Semiconserved Plasmodium falciparum Erythrocyte Membrane Protein 1, VAR4, Predict Protection against Malarial Anemia and Febrile Episodes. Infection and Immunity, 2006, 74, 2867-2875.	2.2	48
131	Dynamics of Antiâ€VAR2CSA Immunoglobulin G Response in a Cohort of Senegalese Pregnant Women. Journal of Infectious Diseases, 2006, 193, 713-720.	4.0	79
132	Differential Expression of var Gene Groups Is Associated with Morbidity Caused by Plasmodium falciparum Infection in Tanzanian Children. Infection and Immunity, 2006, 74, 3904-3911.	2.2	180
133	Epitope Mapping and Topographic Analysis of VAR2CSA DBL3X Involved in P. falciparum Placental Sequestration. PLoS Pathogens, 2006, 2, e124.	4.7	83
134	Clinical pattern of severe Plasmodium falciparum malaria in Sudan in an area characterized by seasonal and unstable malaria transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 243-251.	1.8	37
135	Altitudeâ€Dependent and â€Independent Variations inPlasmodium falciparumPrevalence in Northeastern Tanzania. Journal of Infectious Diseases, 2005, 191, 1589-1598.	4.0	131
136	The roles of thepfcrt 76Tandpfmdr1 86Ymutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Annals of Tropical Medicine and Parasitology, 2005, 99, 441-448.	1.6	29
137	Differential Induction of Immunoglobulin G toPlasmodium falciparumVariant Surface Antigens during the Transmission Season in Daraweesh, Sudan. Journal of Infectious Diseases, 2005, 192, 520-527.	4.0	6
138	High Level ofvar2csaTranscription byPlasmodium falciparumIsolated from the Placenta. Journal of Infectious Diseases, 2005, 192, 331-335.	4.0	162
139	Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method. Malaria Journal, 2005, 4, 61.	2.3	27
140	Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malaria Journal, 2005, 4, 48.	2.3	37
141	Expression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humans. Malaria Journal, 2005, 4, 21.	2.3	95
142	A SIMPLE, HIGH-THROUGHPUT METHOD TO DETECT PLASMODIUM FALCIPARUM SINGLE NUCLEOTIDE POLYMORPHISMS IN THE DIHYDROFOLATE REDUCTASE, DIHYDROPTEROATE SYNTHASE, AND P. FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER GENES USING POLYMERASE CHAIN REACTIONâ€“ AND ENZYME-LINKED IMMUNOSORBENT ASSAYâ€“BASED TECHNOLOGY. American Journal of Tropical Medicine and Hygiene, 2005, 72, 155-162.	1.4	48
143	A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. American Journal of Tropical Medicine and Hygiene, 2005, 72, 155-62.	1.4	36
144	Geographical and Temporal Conservation of Antibody Recognition of Plasmodium falciparum Variant Surface Antigens. Infection and Immunity, 2004, 72, 3531-3535.	2.2	43

#	Article	IF	Citations
145	Plasmodium falciparum Associated with Severe Childhood Malaria Preferentially Expresses PfEMP1 Encoded by Group A var Genes. Journal of Experimental Medicine, 2004, 199, 1179-1190.	8.5	292
146	Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria. Journal of Experimental Medicine, 2004, 200, 1197-1203.	8.5	518
147	Antibodies to the N-Terminal Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Associated with Protection against Clinical Malaria. Infection and Immunity, 2004, 72, 6492-6502.	2.2	95
148	Malaria morbidity and immunity among residents of villages with different Plasmodium falciparum transmission intensity in North-Eastern Tanzania. Malaria Journal, 2004, 3, 26.	2.3	61
149	Eleven years of malaria surveillance in a Sudanese village highlights unexpected variation in individual disease susceptibility and outbreak severity. Parasitology, 2004, 129, 263-271.	1.5	41
150	Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Molecular Microbiology, 2003, 49, 179-191.	2.5	648
151	In vitro selection of Plasmodium falciparum 3D7 for expression of variant surface antigens associated with severe malaria in African children. Parasite Immunology, 2003, 25, 421-427.	1.5	49
152	Novel Plasmodium falciparum malaria vaccines: evidence-based searching for variant surface antigens as candidates for vaccination against pregnancy-associated malaria. Immunology Letters, 2003, 85, 213.	2.5	0
153	Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. Lancet, The, 2003, 361, 1853-1860.	13.7	132
154	Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding regions. Malaria Journal, 2003, 2, 27.	2.3	296
155	Lack of Gender-Specific Antibody Recognition of Products from Domains of a var Gene Implicated in Pregnancy-Associated Plasmodium falciparum Malaria. Infection and Immunity, 2003, 71, 4193-4196.	2.2	20
156	Specificity and Cross-Reactivity of Plasmodium falciparum Variant Surface Antigen-Specific Antibody Responses. Infection and Immunity, 2003, 71, 2296-2296.	2.2	2
157	Malaria-Induced Acquisition of Antibodies to Plasmodium falciparum Variant Surface Antigens. Infection and Immunity, 2002, 70, 2982-2988.	2.2	118
158	In Vivo Switching between Variant Surface Antigens in HumanPlasmodium falciparumInfection. Journal of Infectious Diseases, 2002, 186, 719-722.	4.0	30
159	Plasmodium falciparum Variant Surface Antigen Expression Varies Between Isolates Causing Severe and Nonsevere Malaria and Is Modified by Acquired Immunity. Journal of Immunology, 2002, 168, 3444-3450.	0.8	182
160	A marked seasonality of malaria transmsission in two rural sites in eastern Sudan. Acta Tropica, 2002, 83, 71-82.	2.0	62
161	A sub-family of common and highly conserved Plasmodium falciparum var genes. Molecular and Biochemical Parasitology, 2002, 122, 111-115.	1.1	43
162	Humoral and cellular immune responses to glucose regulated protein 78 - a novel Leishmania donovani antigen. Tropical Medicine and International Health, 2002, 7, 471-476.	2.3	15

#	Article	IF	Citations
163	Novel Plasmodium falciparum malaria vaccines: evidence-based searching for variant surface antigens as candidates for vaccination against pregnancy-associated malaria. Immunology Letters, 2002, 84, 133-136.	2.5	9
164	High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clinical and Experimental Immunology, 2001, 111, 64-69.	2.6	116
165	Inhibition of Fumarate Reductase in Leishmania major and L. donovani by Chalcones. Antimicrobial Agents and Chemotherapy, 2001, 45, 2023-2029.	3.2	189
166	Cloning, expression and antigenicity of the L. donovani reductase. Apmis, 2001, 109, 461-468.	2.0	9
167	Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani. BBA - Proteins and Proteomics, 2001, 1549, 73-87.	2.1	29
168	Insecticide-Treated Bed Nets Reduce Plasma Antibody Levels and Limit the Repertoire of Antibodies to Plasmodium falciparumVariant Surface Antigens. Vaccine Journal, 2001, 8, 1289-1291.	2.6	26
169	Antibodies to Variant Antigens on the Surfaces of Infected Erythrocytes Are Associated with Protection from Malaria in Ghanaian Children. Infection and Immunity, 2001, 69, 3713-3718.	2.2	92
170	Differential Patterns of Human Immunoglobulin G Subclass Responses to Distinct Regions of a Single Protein, the Merozoite Surface Protein 1 of Plasmodium falciparum. Infection and Immunity, 2001, 69, 1207-1211.	2.2	64
171	Selection of Glutamate-Rich Protein Long Synthetic Peptides for Vaccine Development: Antigenicity and Relationship with Clinical Protection and Immunogenicity. Infection and Immunity, 2001, 69, 5223-5229.	2.2	43
172	Chronic Plasmodium falciparum infections in an area of low intensity malaria transmission in the Sudan. Parasitology, 2000, 120, 447-456.	1.5	62
173	The development of post-kala-azar dermal leishmaniasis (PKDL) is associated with acquisition of Leishmania reactivity by peripheral blood mononuclear cells (PBMC). Clinical and Experimental Immunology, 2000, 119, 523-529.	2.6	49
174	Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunology Letters, 2000, 71, 117-126.	2.5	109
175	The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 645-651.	1.8	68
176	Plasma Antibodies from Malaria-Exposed Pregnant Women Recognize Variant Surface Antigens on Plasmodium falciparum-Infected Erythrocytes in a Parity-Dependent Manner and Block Parasite Adhesion to Chondroitin Sulfate A. Journal of Immunology, 2000, 165, 3309-3316.	0.8	280
177	Naturally Acquired Antibodies to the Glutamateâ€Rich Protein Are Associated with Protection againstPlasmodium falciparumMalaria. Journal of Infectious Diseases, 2000, 181, 1202-1205.	4.0	104
178	High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Tropica, 2000, 75, 35-38.	2.0	20
179	Molecular characterization of a Leishmania donovanii cDNA clone with similarity to human 20S proteasome a-type subunit1The sequence data reported in this paper have been submitted to EMBL/GenBank and DDJB data libraries under accession No. AF088882.1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1500, 77-87.	3.8	16
180	The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. Journal of Antimicrobial Chemotherapy, 1999, 43, 793-803.	3.0	165

#	Article	IF	Citations
181	Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 157-160.	1.8	33
182	T-cell response in human leishmaniasis. Immunology Letters, 1999, 65, 105-108.	2.5	81
183	Leishmania-specific T cells expressing interferon-gamma (IFN-Î³) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clinical and Experimental Immunology, 1999, 116, 500-504.	2.6	59
184	Interferon-Î³- and Tumour Necrosis Factor-Î±-Producing Cells in Humans who are Immune to Cutaneous Leishmaniasis. Scandinavian Journal of Immunology, 1999, 49, 655-659.	2.7	36
185	Detection of antibodies to variant antigens onPlasmodium falciparum-infected erythrocytes by flow cytometry. , 1999, 35, 329-336.		157
186	Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. Journal of Pathology, 1999, 189, 615-622.	4.5	58
187	Characterization of the Local and Systemic Immune Responses in Patients with Cutaneous Leishmaniasis Due toLeishmania major. Clinical Immunology, 1999, 91, 314-320.	3.2	46
188	Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by Plasmodium falciparum. Parasitology, 1999, 119, 7-17.	1.5	49
189	Detection of antibodies to variant antigens on Plasmodium falciparumâ€infected erythrocytes by flow cytometry. Cytometry, 1999, 35, 329-336.	1.8	103
190	Levels of Antibody to Conserved Parts ofPlasmodium falciparumMerozoite Surface Protein 1 in Ghanaian Children Are Not Associated with Protection from Clinical Malaria. Infection and Immunity, 1999, 67, 2131-2137.	2.2	108
191	A Longitudinal Study of Human Antibody Responses toPlasmodium falciparumRhoptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission. Infection and Immunity, 1999, 67, 2975-2985.	2.2	30
192	Nine-Year Longitudinal Study of Antibodies to Variant Antigens on the Surface ofPlasmodium falciparum-Infected Erythrocytes. Infection and Immunity, 1999, 67, 4092-4098.	2.2	81
193	TheLeishmaniapromastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity toL. major. FEMS Immunology and Medical Microbiology, 1998, 20, 209-218.	2.7	23
194	Antibody reactivity to conserved linear epitopes of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). Immunology Letters, 1998, 60, 121-126.	2.5	19
195	The potential antileishmanial activity of some Sudanese medicinal plants. Phytotherapy Research, 1998, 12, 576-579.	5.8	50
196	limonoids from Khaya senegalensis. Phytochemistry, 1998, 49, 1769-1772.	2.9	54
197	Malaria in areas of unstable and seasonal transmission. Lessons from Daraweesh. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 589-592.	1.8	42
198	Humoral and Cellular Immune Responses to Synthetic Peptides of theLeishmania donovaniKinetoplastid Membrane Proteinâ€11. Scandinavian Journal of Immunology, 1998, 48, 103-109.	2.7	33

#	Article	IF	Citations
199	Antiprotozoal Properties of 16,17-Dihydroxybrachycalyxolide fromVernonia brachycalyx. Planta Medica, 1998, 64, 559-562.	1.3	41
200	Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology, 1998, 116, 501-510.	1.5	77
201	The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. FEMS Immunology and Medical Microbiology, 1998, 20, 209-218.	2.7	2
202	Two New Antiprotozoal 5-Methylcoumarins fromVernonia brachycalyx. Journal of Natural Products, 1997, 60, 458-461.	3.0	70
203	Modification of T-Cell Antigenic Properties of Tetanus Toxoid by SDS-Page Separation. Implications for T-Cell Blotting. Journal of Immunoassay, 1997, 18, 129-148.	0.3	0
204	Antiprotozoal Compounds from Asparagus africanus. Journal of Natural Products, 1997, 60, 1017-1022.	3.0	83
205	Soluble haemoglobin is a marker of recent Plasmodium falciparum infections. Immunology Letters, 1997, 59, 35-42.	2.5	8
206	Human T-cell recognition of synthetic peptides representing conserved and variant sequences from the merozoite surface protein 2 of Plasmodium falciparum. Immunology Letters, 1997, 58, 1-8.	2.5	13
207	Antibody responses to Rhoptryâ€Associated Proteinâ€1 (RAPâ€1) of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. Parasite Immunology, 1997, 19, 387-393.	1.5	23
208	The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Trends in Immunology, 1996, 17, 13-16.	7.5	95
209	Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 133-135.	1.8	61
210	Random amplified polymorphic DNA for the differentiation of Leishmania donovani isolates from Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 204-205.	1.8	17
211	Detection of Very Low Level Plasmodium falciparum Infections using the Nested Polymerase Chain Reaction and a Reassessment of the Epidemiology of Unstable Malaria in Sudan. American Journal of Tropical Medicine and Hygiene, 1996, 54, 325-331.	1.4	172
212	Interferonâ€Î³ and interleukinâ€4 production by human T cells recognizing Leishmania donovani antigens separated by SDSâ€PAGE. Apmis, 1995, 103, 131-139.	2.0	8
213	Interleukin-4 and Interferon-Gamma Production by Leishmania Stimulated Peripheral Blood Mononuclear Cells from Nonexposed Individuals. Scandinavian Journal of Immunology, 1995, 41, 343-349.	2.7	35
214	Synthesis of antiparasitic licorice chalcones. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 449-452.	2.2	53
215	Diversity among Leishmania isolates from the Sudan: isoenzyme homogeneity of L. donovani versus heterogeneity of L. major. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 366-369.	1.8	13
216	High Proportion of Subclinical Plasmodium falciparum Infections in an Area of Seasonal and Unstable Malaria in Sudan. American Journal of Tropical Medicine and Hygiene, 1995, 53, 78-83.	1.4	32

#	Article	IF	Citations
217	An Antileishmanial Chalcone from Chinese Licorice Roots. Planta Medica, 1994, 60, 121-123.	1.3	37
218	Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Zeitschrift FÃ¼r Parasitenkunde (Berlin, Germany), 1994, 80, 569-574.	0.8	44
219	Differential T-cell expression of LFA-1 in residents from Africa and Denmark. Description of the phenomenon and its possible basis. Immunology Letters, 1994, 39, 147-151.	2.5	4
220	Thl-Like Human T-Cell Clones Recognizing Leishmania gp63 Inhibit Leishmania major in Human Macrophages. Scandinavian Journal of Immunology, 1994, 40, 629-635.	2.7	9
221	Dichotomy in the human CD4⁺ Tâ€cell response to Leishmania parasites. Apmis, 1994, 102, 81-88.	2.0	12
222	Evidence of Endothelial Inflammation, T Cell Activation, and T Cell Reallocation in Uncomplicated Plasmodium Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1994, 51, 372-379.	1.4	47
223	Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-Selectin) during acute Plasmodium falciparum malaria. Immunology Letters, 1993, 36, 51-58.	2.5	46
224	Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. Immunology Letters, 1993, 38, 137-144.	2.5	20
225	Interferonâ€gamma and interleukinâ€4 in human Leishmania donovani infections. Immunology and Cell Biology, 1993, 71, 583-587.	2.3	32
226	The efficacy of artemether in the treatment of Plasmodium falciparum malaria in Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 685-686.	1.8	15
227	A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. Journal of Immunological Methods, 1993, 157, 135-142.	1.4	37
228	Seasonal changes in human immune responses to malaria. Parasitology Today, 1993, 9, 26-27.	3.0	8
229	Seasonal changes in cell mediated immune responses to soluble Plasmodium falciparum antigens in children with haemoglobin AA and haemoglobin AS. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 20-22.	1.8	24
230	Tâ€cell responses in malaria. Apmis, 1992, 100, 95-106.	2.0	10
231	Cellular and Humoral Immune Responses in a Population from the Baringo District, Kenya to Leishmania Promastigote lipophosphoglycan. American Journal of Tropical Medicine and Hygiene, 1992, 46, 480-488.	1.4	35
232	Activation of Human T Lymphocytes by Leishmania Lipophosphoglycan. Scandinavian Journal of Immunology, 1991, 33, 219-224.	2.7	37
233	Lymphoproliferative Responses to Plasmodium falciparum Antigens in Children With and Without the Sickle Cell Trait. Scandinavian Journal of Immunology, 1991, 34, 237-242.	2.7	25
234	Loss of cellular immune reactivity during acutePlasmodium falciparummalaria. FEMS Microbiology Letters, 1991, 76, 219-228.	1.8	51

#	Article	IF	Citations
235	Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acutePlasmodium falciparum malaria. European Journal of Immunology, 1991, 21, 1249-1253.	2.9	80
236	Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiology Letters, 1991, 76, 219-227.	1.8	0
237	Cellâ€mediated immune responses to soluble Plasmodium falciparum antigens in residents from an area of unstable malaria transmission in the Sudan. Apmis, 1990, 98, 594-604.	2.0	18
238	Cell-mediated immune responses to Plasmodium falciparum purified soluble antigens in sickle-cell trait subjects. Immunology Letters, 1990, 25, 243-249.	2.5	33
239	Biochemical characterization, localization and immunostimulating properties of a soluble glycoprotein, Ag1, isolated from in vitro cultures ofPlasmodium falciparum. Zeitschrift FÃ¼r Parasitenkunde (Berlin, Germany), 1990, 76, 657-661.	0.8	5
240	Reduced cellular immune reactivity in healthy individuals during the malaria transmission season. Immunology Letters, 1990, 25, 237-242.	2.5	35
241	Recombinant human tumour necrosis factor is not inhibitory to Plasmodium falciparum in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 48-49.	1.8	11
242	Cell-Mediated Immunity to Plasmodium falciparum Infection: Evidence against the Involvement of Cytotoxic Lymphocytes. Scandinavian Journal of Immunology, 1988, 28, 105-111.	2.7	14
243	Pseudomonas aeruginosa septicaemia in a patient with severe Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987, 81, 49-50.	1.8	12
244	Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. International Journal of Immunopharmacology, 1987, 9, 513-519.	1.1	17
245	Selective Modulation of the CD4 Molecular Complex by Pseudomonas aeruginosa Alkaline Protease and Elastase. Scandinavian Journal of Immunology, 1987, 26, 91-94.	2.7	30
246	Suppression of blood monocyte and neutrophil chemotaxis in acute human malaria. Parasite Immunology, 1986, 8, 541-550.	1.5	16
247	Effect of pyrimethamine and sulphadoxine on human lymphocyte proliferation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986, 80, 295-300.	1.8	10
248	Low parasite specific T cell response in clinically immune individuals with low grade Plasmodium falciparum parasitaemia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1986, 80, 1000-1001.	1.8	20
249	Suppression of Parasite-Specific Response in Plasmodium falciparum Malaria. A Longitudinal Study of Blood Mononculear Cell Proliferation and Subset Composition. Scandinavian Journal of Immunology, 1986, 24, 73-81.	2.7	57
250	Effects of Chloroquine, Mefloquine and Quinine on Natural Killer Cell Activity in vitro.. Allergy: European Journal of Allergy and Clinical Immunology, 1986, 41, 537-542.	5.7	13
251	Effect of praziquantel on human lymphocyte proliferation in vitro. European Journal of Clinical Pharmacology, 1984, 27, 311-313.	1.9	2